| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Chief Executive Officer | Director
4 companies
Cha Albert serves as a Director at ACRS and has filed Form 4s across 4 companies. Across recent SEC filings that breaks down to 18 buys and 1 sell. Those positions are worth an estimated $3.0M at current prices.
The biggest single holding is FLSC (~$3.0M) as Chief Executive Officer. Net of sales, the recent Form 4 record there shows accumulation of 300,000 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 15, 2026 | FLSC Frazier Life Sciences Acquisition Corp. II Class A Ordinary Shares | Chief Executive Officer | Buy | 300,000 | $10.00 | $3,000,000.00 | New | - | - | |
| Sep 11, 2023 | KALV Kalvista Pharmaceuticals, Inc. | Director | Sale+OE | 18,000 | $10.50 | $189,050.40 | -100% | -16.6% | +6.4% | |
| Oct 30, 2020 | KALV Kalvista Pharmaceuticals, Inc. | Director | Buy | 115,686 | $17.24 | $1,994,067.74 | +11.3% | - | - | |
| Jul 29, 2019 | KALV Kalvista Pharmaceuticals, Inc. | Director | Buy | 56,367 | $16.99 | $957,737.10 | +82.7% | - | - | |
| Jul 19, 2019 | KALV Kalvista Pharmaceuticals, Inc. | Director | Buy | 61,280 | $17.79 | $1,090,295.69 | +6.7% | - | - | |
| Sep 10, 2018 | KALV Kalvista Pharmaceuticals, Inc. | Director | Buy | 1,058,824 | $17.00 | $18,000,008.00 | +352.6% | - | - | |
| Jan 25, 2018 | VYNE Vyne Therapeutics Inc. | Director | Buy | 294,118 | $17.00 | $5,000,006.00 | -113.8% | - | - | |
| Oct 13, 2015 | ACRS Aclaris Therapeutics, Inc. | Director | Buy | 454,545 | $11.00 | $4,999,995.00 | +12.2% | - | - | |
| Oct 7, 2015 | ACRS Aclaris Therapeutics, Inc. | Director | Buy | 13,352 | $11.00 | $146,872.00 | +4.6% | - | - | |
| Apr 14, 2015 | KALV Kalvista Pharmaceuticals, Inc. | Director | Buy | 1,012,500 | $5.00 | $5,062,500.00 | +31.7% | - | - |